HSJ Cancer Virtual Event - The impact COVID -19 on cancer services

24th June | 10am - 1.15pm
HSJ Cancer Virtual Event - The impact COVID -19 on cancer services

Prior to the outbreak of the coronavirus pandemic, the Long-term Plan set out ambitious targets to improve cancer outcomes and services in England over the next ten years. Coronavirus has impacted cancer services, due to the pressure on the NHS and the need to shield vulnerable patients from exposure to coronavirus.

In spite of this, the NHS has had to continue to deliver care through cancer services, leading to difficult conversations about whether to treat or delay treatment for cancer patients.

Join HSJ for their first HSJ Cancer Virtual Event on Wednesday, 24 June from 10:00am -1:15pm  for a very current and topical conversation on what is being done now in terms of creating COVID-19-free cancer hubs and to address disrupted treatment pathways.


Creating COVID free cancer hubs - 10:00am - 10:50am

In April, trusts were told to urgently reconfigure cancer services, and consolidate cancer surgery into ‘clean’ COVID-19-free sites to mitigate further delays to procedures. How is this rapid change progressing, and how are trusts achieving this?

Join the panellists, who will be sharing their insight and experience so far and get advice on the challenges within your service.

Disruption to the treatment pathway 1: Surgery - 11:20am - 12:00pm

With the guidance that cancer patients needing treatment should be referred to a clinically led central triage point and then prioritised for surgery – how are regions and cancer alliances managing the change?

Join this panel to hear how other areas are setting the amended pathway up and how others are approaching the difficult decisions on level of clinical need and risk.

Disruption to the treatment pathway 2: Other treatments - 12:30pm - 1:15pm

Recent guidance outlined how treatment decisions would need to be made with input from MDTs and patients on a case by case basis. The decisions require a balance of risk and benefit, and treatment intent. Resource and capacity also need to be taken into account.

Join this session to explore what decisions are being made and how, and to gain insight and best practice from other services.


Roger Spencer
Chief Executive - The Christie FT

John Renninson
Clinical Lead - Peninsula Cancer Alliance

James Catton
Cancer Lead - Nottingham University Hospitals Trust

Dr Richard Simcock
Consultant Clinical Oncologist - Brighton and Sussex University Hospitals Trust

Richard Johnson
Regional Director (Wales) - Royal College of Surgeons

David Long
Business Unit Director, Oncology - MSD

Professor Clare Turnbull
Professor of Cancer Genomics - Institute of Cancer Research (ICR)

Jackie Fenemore
Nurse Clinician; Lung Cancer - The Christie FT

Lois Roberts
Cancer Divisional Manager - UCLH Trust

Register here to access the three panel sessions of the HSJ Cancer Virtual Event, taking place between 10:00am and 1:15pm on Wednesday, 24 June.